VRNA Verona Pharma plc
Price (delayed)
$60.29
Market cap
$5.12B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.16
Enterprise value
$4.95B
Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of respiratory diseases with significant unmet medical needs. If successfully developed and approved,
Highlights
Verona Pharma's gross margin has increased by 4% QoQ
VRNA's equity has surged by 57% since the previous quarter but it is down by 18% year-on-year
The EPS has dropped by 200% year-on-year and by 8% since the previous quarter
Verona Pharma's quick ratio has shrunk by 68% YoY and by 18% QoQ
Key stats
What are the main financial stats of VRNA
Market
Valuations
Earnings
Shares outstanding
84.98M
Market cap
$5.12B
Enterprise value
$4.95B
Price to earnings (P/E)
N/A
Price to book (P/B)
24.12
Price to sales (P/S)
116.27
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
117.14
Revenue
$42.28M
Gross profit
$39.7M
Operating income
-$154.63M
Net income
-$173.42M
EBIT
-$139.59M
EBITDA
-$138.53M
Free cash flow
-$122.78M
Per share
Balance sheet
Liquidity
EPS
-$2.16
EPS diluted
-$2.16
Free cash flow per share
-$1.51
Book value per share
$2.5
Revenue per share
$0.52
TBVPS
$5.81
Total assets
$474.24M
Total liabilities
$269.68M
Debt
$228.81M
Equity
$204.56M
Working capital
$410.89M
Debt to equity
1.12
Current ratio
10.63
Quick ratio
10.1
Net debt/EBITDA
1.23
Margins
Efficiency
Dividend
EBITDA margin
-327.7%
Gross margin
93.9%
Net margin
-410.2%
Operating margin
-365.7%
Return on assets
-43.9%
Return on equity
-95.2%
Return on invested capital
-72.3%
Return on capital employed
-32.3%
Return on sales
-330.2%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
VRNA stock price
How has the Verona Pharma stock price performed over time
Intraday
2.99%
1 week
-6.06%
1 month
-13.41%
1 year
278.47%
YTD
29.82%
QTD
-5.04%
Financial performance
How have Verona Pharma's revenue and profit performed over time
Revenue
$42.28M
Gross profit
$39.7M
Operating income
-$154.63M
Net income
-$173.42M
Gross margin
93.9%
Net margin
-410.2%
The operating income has plunged by 129% YoY
The operating margin has soared by 87% from the previous quarter
The net margin has soared by 85% since the previous quarter
VRNA's net income is down by 13% QoQ
Growth
What is Verona Pharma's growth rate over time
Valuation
What is Verona Pharma stock price valuation
P/E
N/A
P/B
24.12
P/S
116.27
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
117.14
The EPS has dropped by 200% year-on-year and by 8% since the previous quarter
VRNA's P/B is 90% above its last 4 quarters average of 12.3
VRNA's equity has surged by 57% since the previous quarter but it is down by 18% year-on-year
Efficiency
How efficient is Verona Pharma business performance
Verona Pharma's ROA has plunged by 148% YoY
The return on sales has surged by 87% since the previous quarter
The ROIC has grown by 33% YoY and by 23% from the previous quarter
Verona Pharma's ROE has decreased by 20% from the previous quarter
Dividends
What is VRNA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for VRNA.
Financial health
How did Verona Pharma financials performed over time
Verona Pharma's total assets is 76% more than its total liabilities
Verona Pharma's current ratio has plunged by 68% YoY and by 18% from the previous quarter
Verona Pharma's quick ratio has shrunk by 68% YoY and by 18% QoQ
The debt is 12% greater than the equity
VRNA's equity has surged by 57% since the previous quarter but it is down by 18% year-on-year
Verona Pharma's debt to equity has decreased by 35% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.